BOSTON, MA — Aug 7, 2026 — Insilico Medicine and the ARDD organizing committee are pleased to announce that Ruth Gimeno, VP Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development at Eli Lilly, will be a featured speaker at the 13th Aging Research & Drug Discovery (ARDD) Meeting. This landmark event will take place from October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University.
As longevity science transitions from theoretical concepts to multi-billion-dollar therapeutic pipelines, ARDD 2026 stands as the premier global nexus connecting academic researchers, clinical investigators, leading pharmaceutical companies, and institutional investors.
"The biology of aging has become one of the most promising frontiers in biomedical science. Our challenge is to both better understand it and translate fundamental discoveries into interventions that improve healthspan. That will require an unprecedented level of collaboration across disciplines and sectors,” said Vadim Gladyshev, Executive Chair of ARDD and Professor of Medicine at Harvard University. “Conferences like ARDD play an important role by bringing together the people who can ask difficult questions, test new ideas, and build the partnerships needed to advance the field."
With visionary presenters sharing their insights alongside leaders from ten of the world's top pharmaceutical companies, ARDD 2026 is an unmatched catalyst for translating longevity science into real-world medicine.
“ARDD has always been about bringing together the world's leading minds in aging research to accelerate the development of interventions that extend healthy lifespan. Moving ARDD to Boston marks an exciting new chapter, placing the conference at the heart of one of the world's strongest biomedical innovation ecosystems. At the same time, ARDD 2026 reflects the field's increasing maturity, with an incredibly strong focus on translating scientific discoveries into medicines. The future is bright.” Morten
Officially organized by Insilico Medicine, the 2026 meeting is anchored by Tier 1 sponsors Insilico Medicine and Eli Lilly, with the McKinsey Health Institute joining as the Sole Knowledge Partner. The conference brings together a highly curated ecosystem of academic leaders, biotechnology innovators, pharmaceutical companies, entrepreneurs, and investors, including Tier 3 sponsors AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health, and TruDiagnostic. Synaro Capital, The Cat Health Company, and PranaGen Bioscience support the event as Tier 4 sponsors, alongside Tier 5 sponsors Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity, and QuadraScope.
“For over a decade, ARDD has served as the primary global platform for academia-pharma-startup-investor dialogue,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “The massive momentum driving this year's meeting in Boston underscores that longevity biotechnology has become a foundational pillar of modern drug discovery and health economics.”
For further information or interview requests with the speakers, please contact: ardd@pharma.ai
The Aging Research & Drug Discovery (ARDD) Meeting is the world's largest meeting dedicated to aging and longevity biotechnology. Now in its 13th year, ARDD brings together researchers, clinicians, biotechnology and pharmaceutical leaders, entrepreneurs, investors, and policymakers from around the world to accelerate the translation of breakthroughs in the biology of aging into practical R&D and therapeutic programs. The 2026 meeting will take place October 1–3 at the David Rubenstein Treehouse at Harvard University in Boston. Learn more at agingpharma.org.
The Nordic Aging Society is a supporter of ARDD and a non-profit scientific organization dedicated to advancing research on the biology of aging and promoting collaboration among researchers, clinicians, and industry across the Nordic region and beyond.